{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:12Z","timestamp":1791414132261,"version":"4.3.3"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100019428","name":"Nabriva Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019428","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>\n            Lefamulin, the first semisynthetic pleuromutilin antibacterial for intravenous and oral treatment of community-acquired bacterial pneumonia (CABP), and comparators were evaluated for\n            <jats:italic>in vitro<\/jats:italic>\n            activity against a global collection of pathogens commonly causing CABP (\n            <jats:italic>n<\/jats:italic>\n            = 8595) from the 2015 and 2016 SENTRY Antimicrobial Surveillance Program. Lefamulin was highly active against the pathogens\n            <jats:named-content content-type=\"genus-species\">Streptococcus pneumoniae<\/jats:named-content>\n            , including multidrug-resistant and extensively drug-resistant strains (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            for total and resistant subsets, 0.06\/0.12 \u03bcg\/ml; 100% inhibited at \u22641 \u03bcg\/ml),\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            , including methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA; both MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml; 99.8% and 99.6% inhibited at \u22641 \u03bcg\/ml, respectively),\n            <jats:named-content content-type=\"genus-species\">Haemophilus influenzae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/1 \u03bcg\/ml; 93.8% inhibited at \u22641 \u03bcg\/ml), and\n            <jats:named-content content-type=\"genus-species\">Moraxella catarrhalis<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml; 100% inhibited at \u22640.25 \u03bcg\/ml), and its activity was unaffected by resistance to other antibacterial classes.\n          <\/jats:p>","DOI":"10.1128\/aac.02161-18","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T15:19:03Z","timestamp":1548256743000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015\u20132016)"],"prefix":"10.1128","volume":"63","author":[{"given":"Susanne","family":"Paukner","sequence":"first","affiliation":[{"name":"Nabriva Therapeutics GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Gelone","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J. Ryan","family":"Arends","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","first-page":"494","article-title":"The incidence rate and economic burden of community-acquired pneumonia in a working-age population","volume":"6","author":"Broulette J","year":"2013","unstructured":"Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. 2013. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits 6:494\u2013503.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_3_2","volume-title":"The European lung white book: respiratory health and disease in Europe","author":"Gibson J","year":"2013","unstructured":"Gibson J. 2013. The European lung white book: respiratory health and disease in Europe, 2nd ed. European Respiratory Society, Sheffield, United Kingdom.","edition":"2"},{"key":"e_1_3_3_4_2","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. 2015. Pneumococcal disease. In Hamborsky J, Kroger A, Wolfe S (ed), Epidemiology and prevention of vaccine-preventable diseases, 13th ed. Public Health Foundation, Washington, DC.","edition":"13"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.03.2130"},{"key":"e_1_3_3_6_2","first-page":"S3","article-title":"Assessment of specific risk scores for patients admitted to the ICU for severe community-acquired pneumonia","volume":"19","author":"Joya-Montosa C","year":"2015","unstructured":"Joya-Montosa C, Delgado-Amaya MD, Trujillo-Garcia E, Curiel-Balsera E. 2015. Assessment of specific risk scores for patients admitted to the ICU for severe community-acquired pneumonia. Critical Care 19:S3.","journal-title":"Critical Care"},{"key":"e_1_3_3_7_2","volume-title":"Deaths: final data for 2016","author":"Xu J","year":"2018","unstructured":"Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. 2018. Deaths: final data for 2016, vol. 67, no. 5. National Center for Health Statistics, Hyattsville, MD."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.s2.5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2019.1562339"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0062-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.794805"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2017.1279012"},{"key":"e_1_3_3_16_2","volume-title":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. 2016. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. U.S. Food and Drug Administration, Silver Spring, MD. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm511530.htm."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep39004"},{"key":"e_1_3_3_18_2","volume-title":"Antibiotics and antibiotic resistance","author":"Paukner S","year":"2016","unstructured":"Paukner S, Riedl R. 2016. Pleuromutilins: potent drugs for resistant bugs\u2014mode of action and resistance. In Silver L, Bush K (ed), Antibiotics and antibiotic resistance. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02008-16"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks001"},{"key":"e_1_3_3_21_2","article-title":"Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing","author":"Wicha WW","unstructured":"Wicha WW, Prince WT, Lell C, Heilmayer W, Gelone SP. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother, in press.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv442"},{"key":"e_1_3_3_23_2","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia","author":"Bhavnani SM","unstructured":"Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG. Pharmacokinetic-pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia. J Antimicrob Chemother, in press.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_3_24_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A10, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_3_25_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 28th informational supplement, M100Ed28E","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement, M100Ed28E. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_26_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 8.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2018","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2018. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00358-13"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00627-16"},{"key":"e_1_3_3_29_2","volume-title":"ASM Microbe","author":"File T","year":"2018","unstructured":"File T, Goldberg L, Das A, Sweeney C, Saviski J, Gelone S, Seltzer E, Talbot G, Gasink L. 2018. Lefamulin is non-inferior to moxifloxacin in adults with community-acquired bacterial pneumonia (CABP): the phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) study. ASM Microbe, Atlanta, GA."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy229.2180"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv107"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02161-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02161-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:43:09Z","timestamp":1645479789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02161-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1128\/AAC.02161-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02161-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02161-18"}}